Premium
Molecular correlates in AIDS patients following antiretroviral therapy: diversified T‐cell receptor repertoires and in vivo control of cytomegalovirus replication
Author(s) -
Worrell S,
Deayton J,
Hayes P,
Emery Vc,
Gotch F,
Gazzard B,
LarssonSciard EL
Publication year - 2001
Publication title -
hiv medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 79
eISSN - 1468-1293
pISSN - 1464-2662
DOI - 10.1046/j.1468-1293.2001.00044.x
Subject(s) - t cell receptor , cd8 , immunology , cd28 , medicine , ex vivo , t cell , immune system , in vivo , cytotoxic t cell , virology , biology , in vitro , genetics
1Department of Immunology and2The Kobler Centre, Chelsea and Westminster Hospital, and3Royal Free Hospital and University College Medical School, London, UKObjectives To evaluate whether successful, long‐term immune reconstitution in vivo can be achieved in end‐stage AIDS patients following antiretroviral therapy (ART). Methods A 1‐year prospective study of changes of CD4+ and CD8+ T‐cell surface phenotypes, T‐cell receptor (TCR) repertoires and capacity to control in vivo replication of cytomegalovirus (CMV) was performed in five treatment‐naive end‐stage AIDS patients (median CD4+ T‐cell counts of 19 cells/μL) following therapy. Proportions of CD45RA+, CD45RO+ and CD28+ cells within the CD4+ and CD8+ subsets, were determined by flow cytometry. Changes in TCR Vβ repertoires within the CD4+ and CD8+ T‐cell compartments were evaluated using CDR3 spectratyping. CMV replication was determined by a sensitive polymerase chain reaction (PCR) assay using whole blood. Results Following ART, proportionate increases in ‘naive’ (CD45RA+) and ‘memory’ (CD45RO+) T cells were observed within both CD4+ and CD8+ T‐cell subsets, while increased numbers of CD28+ T cells were mainly observed within the CD4+ subset. Diversification of CD4+ and CD8+ TCR repertoires was established concomitantly with renewed in vivo control of CMV replication. Conclusions An important degree of molecular and functional immune recovery is possible in end‐stage AIDS patients introduced to therapy. Diversification of TCR repertoires and the in vivo restoration of immunocompetence to control opportunistic infections clearly show that an important degree of molecular immune reconstitution is established following the initiation of ART even in late‐stage AIDS.